Clinical Researcher

When writing SOPs, it’s important to strike the right balance between providing enough detail and avoiding excessive complexity. Insufficient detail increases the likelihood of users improvising on the spot or following widely used, but perhaps inadequate, methods. On the other hand, excessive information can lead to confusion, errors, and mistakes.

It is not always a smooth ride when a company is navigating the acquisition and fusion of disparate cultures, specialties, and other variables from formerly separate organizations. But the process can bring a hybrid vigor when new professionals are integrated into one's corporate family. Just as the science of clinical trials benefits from patient diversity, so does the workforce and the broader industry.

Among the myriad challenges to researchers of specialty drugs and cell and gene therapies are the unique requirements of these new, innovative products and the burdens tied to establishing protocols for flexible, agile supply chain logistics in support of their research and development.

A glimpse into some of the facts and figures at play in the comings and goings of today's clinical research enterprise.

This study explored the experiences of clinical research principal investigators (PIs) in addressing diversity in clinical trials. The PI respondents, recruited through social media and professional networks, shared their insights through interviews.